tbuckley/cabot-search huggingface dataset:
P92 Systemic alkyl quinolones as novel biomarkers for pulmonary exacerbations in cystic fibrosis: a validation study
Authors: H Barr, A Fogarty, N Halliday, A Knox, B Quon, D Forrester, P Williams, D Barrett, M Camara
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> There is a clinical need to identify and validate biomarkers that are sensitive to treatment of infection in cystic fibrosis (CF). The aim of this study was to externally validate two novel biomarkers for pulmonary exacerbations in CF of the alkyl quinolone (AQ) class of quorum sensing molecules produced by <i>Pseudomonas aeruginosa</i>. <h3>Methods</h3> Retrospective analysis of 70 plasma samples from thirteen adults with CF obtained during treatment of fifteen discrete exacerbations treated with intravenous antibiotics. Plasma samples were obtained at the start, day five, day ten, at the end of treatment, and at clinical stability. Samples were analysed using liquid chromatography-mass spectrometry. Data were analysed using Spearman’s rank correlations and Wilcoxon matched pairs signed-rank tests using STATA 11 statistical software (Texas, USA). Graphs were produced in EXCEL 2011. <h3>Results</h3> Plasma 2-heptyl-4-hydroxyquinoline (HHQ) concentration significantly decreased by a median of 221 pmol/L (IQR: 158 to 258 pmol/L) or 73% (IQR 52 to 94%; p = 0.0007) during treatment for a pulmonary exacerbation (Figure 1). In the same interval, there was no significant change in plasma NHQ (median decrease of −3 pmol/L; IQR: −35 to 10 pmol/L; p = 0.65). During treatment for a pulmonary exacerbation, percent predicted FEV1 increased by 4% (IQR: 1 to 7%; p = 0.0086). Folloing systemic antimicrobial therapy, systemic IL6 concentration decreased by a median of 2.06 pg/mL (IQR: 1.02 to 3.55 pg/mL; p = 0.0022) and systemic calprotectin decreased by 1687 ng/mL (IQR: 291 to 3992 ng/mL; p = 0.0229). There was no significant association between change in plasma HHQ and change in FEV1 during treatment of a pulmonary exacerbation (Spearman’s correlation co-efficient, r = −0.42; p = 0.15). <h3>Conclusions</h3> Plasma HHQ declined significantly during treatment of a pulmonary exacerbation and merits further investigation as a biomarker for measuring treatment response in CF. There was no significant decline in plasma NHQ during systemic antimicrobial therapy.
Methylation in the Promoter Region and Expression of FOX-P3 Correlate with Graft Versus Host Disease, Relapse and Survival after Allogeneic Stem Cell Transplantation
Authors: Cintia Manzano Gonzalez, Pascual Balsalobre, David Serrano, Gabriela Rodriguez Macias, Alfonso Gomez- Pineda, Jose L. Diez-Martin, Ismael Buno
Journal: Blood (2008)
P3.03-001 Targeting Cullin Ubiquitin Ligase Leads to Growths Arrest in Malignant Pleural Mesothelioma Cells
Authors: Mayura Meerang, Jessica Kreienbühl, Martina Friess, Michaela Kirschner, Walter Weder, Isabelle Opitz
Journal: Journal of Thoracic Oncology (2017)
P2.06-036 LUNAR - A Phase 3 Trial of TTFields in Combination with PD-1 Inhibitors or Docetaxel for 2nd Line Treatment of Non-Small-Cell Lung Cancer (NSCLC)
Authors: Uri Weinberg, Ori Farber, Moshe Giladi, Zeev Bomzon, Eilon Kirson
Journal: Journal of Thoracic Oncology (2017)
Renal safety with pamidronate (PAM) 1-hour infusion for metastatic breast cancer (MBC) and multiple myeloma (MM): A multi-centre, population-based analysis
Authors: S. C. M. Taylor, M. L. De Lemos, J. Barnett, F. Hu, S. E. Oreilly
Journal: Journal of Clinical Oncology (2004)

6042 Background: ASCO guidelines recommend PAM be infused over 2 hours to avoid renal deterioration (RD). BCCA recommends 1-hr PAM infusions based on safety from two case series, one randomized controlled trial (RCT) (ASCO 1999 abstract 2223) and one retrospective analysis (ASCO 2002 abstract 208). Longer PAM infusions can affect the optimal use of healthcare resources. Methods: Prevalence of RD (≥ 2 times baseline serum creatinine [SCr)]) with 1-hr PAM infusions between Jan 2000-Dec 2002 from the BCCA registry and systemic therapy drug database was compared to that with 2-hr PAM infusions in RCTs. A cost-minimization analysis comparing the 1- and 2-hr PAM infusions and the 15-minute infusion of zoledronic acid (ZA) was performed with a sensitivity analysis that varied the opportunity cost of time in the treatment room. Results: RD occurred in 10.4% of 144 patients: 15.5% (13/87) in MM, 3.5% (2/57) in MBC. There is no evidence that this differs from the 10% reported in RCTs (one-tailed binomial test, p=0.4741). Increase in SCr was not normally distributed: median increase = 14% in MM and 13% in MBC patients, respectively. The respective costs/dose (drug/labour/supplies) of PAM and ZA are $325 and $610CDN. Cost neutrality occurs if the opportunity cost of chair time is $6.33/min for PAM 1-hr vs ZA and $2.71/min for PAM 2-hr vs ZA. If a median $4/min is used, the respective costs of PAM 1-hr, 2-hr, and ZA infusions become: $685, $790, and $925. Conclusions: Prevalence of RD with 1-hr PAM infusions from a population database was not different than that with 2-hr PAM infusions in RCTs. Our findings further support the safety of 1-hr PAM infusions. PAM via 1-hr infusion is less expensive than ZA. No significant financial relationships to disclose.
P1.05-020 Opposing Prognostic Roles of CD73 and A2A Adenosine Receptor in Non-Small-Cell Lung Cancer
Authors: Yusuke Inoue, Katsuhiro Yoshimura, Nobuya Kurabe, Tomoaki Kahyo, Akikazu Kawase, Masayuki Tanahashi, Hiroshi Ogawa, Naoki Inui, Kazuhito Funai, Kazuya Shinmura, Hiroshi Niwa, Takafumi Suda, Haruhiko Sugimura
Journal: Journal of Thoracic Oncology (2017)
Late Breaking Poster Discussion Session LB PDS 1
Authors: Dibek Misirlioglu, ; Capanoglu, ; Vezir, ; Toyran, ; Kocabas, M€ Obs, C Brick, D Sch€, C Pfu, ; Misirlioglu, ; Civelek, ; Guvenir, ; Ginis, J-H Kim, J Park, Y-B Park, S Hwang, Yi Jang, Sh Jung, ; Stamataki, ; Xepapadaki, ; Sintobin, ; Lukkarinen, ; Jartti, ; Zimmerman, ; Finotto, ; Sobanska, ; Kowalski, ; Papadopoulos, Mon ˜ino Romero, ; Bannert, ; Schmidthaler, ; Eiwegger, ; Dehlink, ; Fiocchi, ; Amoah, ; Yazdanbakhsh, ; Bohle, ; Fiebiger, ; Sz, ; Asuming-Brempong, ; Sartono, ; Reichardt, ; Van Ree, A Van Diepen, ; Hokke
Journal: Allergy (2015)

Background:The most common cause of drug related hypersensitivity reactions in children is beta lactam antibiotics.However, non-beta lactam (NBL) antibiotics may lead to hypersensitivity reactions as well.The aim of this study is to evaluate the characteristics and test results of the patients who were evaluated in our clinic for suspected NBL hypersensitivity.Method: The patients with suspected NBL antibiotic allergy were assessed between January 1st, 2011 and March 15th, 2015.Group of NBL antibiotic, characteristics of the reaction and results of skin test and provocation tests were recorded.Results: Total of 54 patients was assessed.Age of the patients, were 88.17 AE 103.31 (min-max: 5-720) months, whom 42.6% were male.Clarithromycin (57.4%) was the most common cause of the reactions.Twenty four patients (44.4%) had immediate reactions.After ingestion of NBL, maculopapular rash, urticaria/angioedema and anaphylaxis were developed in 29%, 25% and 7% of the patients, respectively.Tests were done in 48 patients.Intradermal tests were positive in 2 patients (with ciprofloxacin and trimethoprim-sulfamethoxazole) and oral provocation test was positive in 1 of the patients (with clarithromycin).Six patients (3 with anaphylaxis, the 3 with urticaria/angioedema) had to take their medications at the time of the reaction so desensitization was performed.These patients could not be tested.When patients who could not be tested were included, the frequency of the NBL allergy was 16.6% (9/54).However, when only patients confirmed by tests were evaluated, the frequency was 6.3% (3/48) in our study.Conclusion: Studies related to NBL allergy in children is limited.Most of the patients with suspected NBL do not have true hypersensitivity and this can be uncovered by skin and drug provocation tests.
P3.02b-069 To Assess Efficacy of First Line TKIs in EGFR Mutant Advanced NSCLC Patients from North India
Authors: Ullas Batra, Pankaj Goyal, Manish Sharma, Mohit Aggarwal, Parveen Jain, Akhil Jain, Rajat Bajaj
Journal: Journal of Thoracic Oncology (2017)
Are there any candidates for adjuvant hysterectomy among patients with locally advanced bulky cervical cancer initially treated with cisplatin-based chemoradiation?
Authors: S. Y. Ryu, W. Lee, K. Kim, S. Park, B. Kim, M. Kim, S. Choi, B. Nam, C. Cho
Journal: Journal of Clinical Oncology (2011)

e15504 Background: Locally advanced bulky cervical cancer (LABCC) is characterized by poor local control. The objective of this study was to identify the clinicopathologic variables associated with 1-year central-only recurrence, which will serve as criteria for adjuvant hysterectomy after radiation (AHR) in patients with LABCC. Methods: Between January 2000 and August 2007, we retrospectively evaluated outcomes in 225 patients with LABCC who were initially treated with radiation or chemoradiation. Results: Among the 225 patients with LABCC, there were 41 recurrences within 1 year following treatment (8 central-only and 33 pelvis and/or distant site recurrences). Age, stage, and treatment type were not associated with the 1-year central-only recurrences; however, tumor size ≥ 8 cm had a statistically significant association based on multivariate analysis (OR, 5.39; 95% CI, 1.15-25.31; p=0.03). The combination of non-squamous cell (non-SCC) type and tumor size ≥ 8 cm had a significantly higher recurrence within 1 year (OR, 43.0; 95% CI, 4.78-386.68; p < 0.01). Conclusions: Of patients with LABCC, those with non-SCC tumors ≥ 8 cm in size were at high risk for early central-only recurrence after cisplatin-based chemoradiation and represent the subset of patients for whom AHR is beneficial.
The P2Y6-AMPK Pathway Triggers Autophagy during CSF-1-Induced Human Monocyte Differentiation and Is a Potential Target in CMML
Authors: Sandrine Obba, Zoheir Hizir, Dorothée Selimoglu-Buet, Laurent Boyer, Anja Pfeifer, Mohamed-Amine Hamouda, Diogo Goncalves, Michael Cerezo, Sandrine Marchetti, Stephane Rocchi, Nathalie Droin, Guillaume Robert, Frederic Luciano, Bernard Robaye, Benoit Viollet, Laurence Legros, Eric Solary, Patrick Auberger, Arnaud Jacquel
Journal: Blood (2014)
Comparative Proteomic Profiling of Refractory/Relapsed Multiple Myeloma Patient Plasma Cells Reveals Biomarkers and Pathways Involved in Bortezomib-Based-Therapy Resistance
Authors: Dominik Dytfeld, Magdalena Luczak, Anna Przybylowicz-Chalecka, Blazej Ratajczak, Adam Nowicki, Joanna Czerwinska-Rybak, Monika Joks, Tomasz Szczepaniak, Bochenek Maciej, Andrzej Jakubowiak, Mieczyslaw Komarnicki
Journal: Blood (2015)
Constitutive Cyclin A1 Expression Induces Abrogation of Cell Cycle Check Points Associated with Ara-C Resistance in Myeloid Leukemia Cells.
Authors: Tsuyoshi Nakamaki, Kunihiko Fukuchi, Norimichi Hattori, Hidetoshi Nakashima, Takashi Maeda, Kouji Yanagisawa, Bungo Saito, Isao Matsuda, Shigeru Tomoyasu
Journal: Blood (2009)
Gene Expression Profiling (GEP) of Whole Bone Marrow Biopsies (BMB) in Multiple Myeloma (MM) – Relationship to Plasma-Cell (PC)-Based GEP-Defined Risk and Molecular Subgroups
Authors: Donald Johann, Pingping Qu, Rachael Sexton, Antje Hoering, Joshua Epstein, Shmuel Yaccoby, Frits van Rhee, Saad Z Usmani, John Crowley, Bart Barlogie
Journal: Blood (2012)
Inhibition of Axl Kinase Reverses the Mesenchymal Phenotype in Leukemic Cells through the Disruption of Retinoic Acid Signaling
Authors: Katherine K. Soh, Brigham L. Bahr, Jeremiah J. Bearss, Wontak Kim, Peter Peterson, Clifford J. Whatcott, Adam Siddiqui-Jain, David J. Bearss, Steven L. Warner
Journal: Blood (2015)
P187 Potential impact of non-arterial blood gas sampling on clinical practice
Authors: RW Thomas, NP Kelly, RT Abraham, GH Jones
Journal: Thorax (2016)

<h3>Introduction</h3> Arterial blood gas (ABG) analysis is commonly used to monitor patients with acute respiratory problems but can be painful and associated with potentially serious side-effects. Recently there has been renewed interest in non-arterial forms of blood gas analysis with a suggestion that such techniques could replace &gt;60% of ABGs.<sup>1</sup> It is however difficult to quantify the impact that non-ABG sampling could have as there is little published data on the clinical burden that ABGs represent. We were interested in establishing how many ABGs are routinely done in a real world setting. <h3>Methods</h3> We retrospectively analysed acute admissions (all cause) to a ward based level 2 Respiratory Emergency Care Unit (RECU) at a University Teaching Hospital over a 6 month period. Prospectively we analysed visual analogue pain scores (VAS) and complications including attempt rates. <h3>Results</h3> Over a 6month period (Apr-Oct) 57 of 111 patients admitted to the RECU had complete datasets. A total of 432 ABGs were obtained from this cohort giving an average of 7.6 ABGs (range 2 – 22) per patient per admission and on average patients had 2.3 ABGs each day whilst on RECU. Overall the mean number of attempts per ABG of the prospectively collected cohort (n = 100) was 1.6 (range 1 – 8; 44% physician obtained). Taking this into account a patient could therefore expect to be stabbed 3.7 times every day or 11 times in total during their admission through the RECU. The most commonly documented complication amongst our patients was pain but average pain scores were relatively low in keeping with other published data (median VAS = 3, IQR 5); no serious complications were reported. <h3>Conclusions</h3> Our data suggests that patients requiring admission to a level 2 respiratory unit experience a high burden of ABG testing during their stay. Using published literature on the potential impact of Non-ABG sampling our data suggests that &gt;500 ABGs could be avoided each year on our acute respiratory unit alone. <h3>Reference</h3> McKeever T, Hearson G, Housley G, <i>et al</i>. Using venous blood gas analysis in the assessment of COPD exacerbations: a prospective cohort study. <i>Thorax</i> 2016;<b>71</b>(3):210–5.
P2.06-013 Afatinib in Patients with Advanced HER2 Mutation-Positive (M+) NSCLC Previously Treated with Chemotherapy
Authors: Caicun Zhou, Yun Fan, Huijuan Wang, Chong Kin Liam, Chengjie Hu, Agnieszka Cseh
Journal: Journal of Thoracic Oncology (2017)
Abstract A20: The DNA damage-induced phosphoproteome is modulated by inhibition of the MET receptor
Authors: Ariel Bensimon, Yitzhak Zimmer, Paola Francica, Jonas P. Koch, Astrid A. Glück, Daniel M. Aebersold, Ruedi Aebersold, Michaela Medova
Journal: Clinical Cancer Research (2017)

Abstract Ionizing radiation (IR) is frequently used in the treatment of a variety of malignant tumors of different origins and stages. In recent years, numerous studies have demonstrated that interfering with signaling via growth factor receptor tyrosine kinases (RTKs) can increase the sensitivity of certain tumors to IR. The RTK for hepatocyte growth factor MET is aberrantly activated in numerous types of human malignancies. MET inhibition has been shown to synergize with DNA damaging agents in generation of DNA damage and to interfere with damage repair. In this study, we aimed to explore how the cellular response to ionizing radiation is modulated by MET inhibition. We have conducted an immunoaffinity-based LC-MS/MS phosphoproteomics survey study to explore the cellular phosphoproteome following exposure of MET-addicted cancer cells to MET inhibition alone and in combination with IR. Phosphorylation sites of interest have been examined using selected reaction monitoring (SRM) and further validated in vitro and in vivo by Western blotting and immunohistochemistry, respectively. Analysis of the survey data has identified more than 300 phosphopeptides which have changed in one experimental condition or more. Several of these phosphorylation changes have been confirmed and further investigated by targeted proteomics. These results have pointed to a sub-network of the DNA damage response (DDR) that is modulated in MET-addicted cancer cells upon DNA damage and MET inhibition. The resulting molecular signature present solely in MET-addicted systems could be responsible for the synergism observed between MET inhibition and DNA-damaging agents. We believe that these results will aid in understanding as how MET signaling crosstalks with the DDR with subsequent translational therapeutic clinical applications. Citation Format: Ariel Bensimon, Yitzhak Zimmer, Paola Francica, Jonas P. Koch, Astrid A. Glück, Daniel M. Aebersold, Ruedi Aebersold, Michaela Medova. The DNA damage-induced phosphoproteome is modulated by inhibition of the MET receptor. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr A20.
S117 Work-related symptoms in laboratory animal workers
Authors: J Feary, J Canizales, C Fitzgerald, B Fitzgerald, S Schofield, M Jones, P Cullinan
Journal: Thorax (2016)

<h3>Introduction</h3> Laboratory animal workers frequently report ocular, nasal and respiratory symptoms which occur in the workplace and improve away from work. A proportion of these will be sensitised to animal proteins on the basis of skin prick tests (SPTs) or serum specific IgE testing and will have laboratory animal allergy. The remainder will have work-related symptoms due to other (unknown) causes. <h3>Methods</h3> We performed a cross-sectional study (SPIRAL (Safe Practice In Reducing Allery in Laboratories)) of laboratory animal workers exposed to mice across six UK research institutions. Participants completed a self-administered questionnaire, which included detailed questions about symptoms, and underwent SPT to common aeroallergens and mouse epithelium, and specific IgE testing to mouse proteins (epithelium and urine). Those participants reporting ocular, nasal or respiratory symptoms which were worse at work were compared with those with no association between their symptoms and work. <h3>Results</h3> 685 laboratory workers were recruited (response rate 88%). 187 (28%) reported at least one symptom and of these, 45% (n = 85) were work-related (WR). 56/105 (53%) reported work-related conjunctivitis; 67/156 (43%) reported WR nasal symptoms and 22/44 (50%) reported WR respiratory symptoms. There were no differences between the two groups in sex, smoking status, atopy to a common aeroallergen or job title. Those with at least one WR symptom were significantly more likely to be sensitisied to mouse proteins (32 (37.7%) vs 10 (9.8%) p &lt; 0.001 (Table). WR symptoms were significantly more common in those working with mice housed in open cages compared with those housed in Individual Ventilated Cages (IVCs) Prevalence of sensitisation to a common aeroallergen was similar in both groups. <h3>Conclusion</h3> In this large study population, prevalence of WR symptoms is reasonably high in all laboratory animal workers and is attributable to mouse allergy in around 50% of cases, consistent with other previous studies. Symptoms are less prominent in people working with IVCs compared with conventional open cages. Exposure to airborne endotoxin may be a cause for nasal and respiratory symptoms on exposure to mice in non-mouse sensitised animal workers. Measurement of exposure to endotoxin levels in these workers is in progress.
PUB016 A Multi-National Cohort Validation of Procedure–Specific Nomograms to Predict Recurrence for Small Lung Adenocarcinomas
Authors: Sarina Bains, Takashi Eguchi, Arne Warth, Yi-Chen Yeh, Jun-Ichi Nitadori, Kaitlin Woo, Teh Ying Chou, Hendrik Dienemann, Thomas Muley, Jun Nakajima, Aya Shinozaki-Ushiku, Yu-Chung Wu, Kyuichi Kadota, William Travis, Kay See Tan, David Jones, Prasad Adusumilli
Journal: Journal of Thoracic Oncology (2017)
Multicenter analysis of more than 300 very elderly non-Hodgkin lymphoma (NHL) patients (pts): Impact of comorbidities and functional status on outcome.
Authors: C. Nabhan, S. M. Smith, I. B. Helenowski, E. E. Ramsdale, R. Karmali, B. M. Parsons, J. Feliciano, B. Hanson, S. E. Smith, J. M. Mckoy, A. Larsen, A. Hantel, S. A. Gregory, A. M. Evens
Journal: Journal of Clinical Oncology (2011)

8042 Background: Ages > 80 represent the most rapidly growing segment of society. Incidence of NHL rises exponentially with age; however, sparse data exist among the > 80 pt group. Methods: We completed a multicenter retrospective study with initial NHL diagnosis = > age 80 (1999 – 2009). Comorbidities were scored with the Cumulative Illness Rating Scale/Geriatrics (CIRS-G). Geriatric syndromes and activity of daily livings (ADLs) were recorded. Results: 303 pts: 170 aggressive (Agg) (143 B-cell) and 133 indolent (Ind) (109 B-cell). Median age was 83 (80-95), 52% stage III/IV, and PS 2-4 in 27%. A geriatric syndrome was present in 26%, 30% were non-fit, 18% had 1 CIRS-G grade 4, while 14% had loss of ADLs. 66% of Agg B-cell received rituximab (R) based therapy (Tx). For Ind NHL, 39% were observed for median of 26 months; when Tx, R-based programs was used in 44%. Overall response (OR) was 65% (44% CR) in Agg and 60% (32% CR) in Tx Ind pts. At 49-month median F/U (6-149), 4-year PFS and OS for Agg were 31% and 44%, respectively (stage I/II: PFS 53%/OS 66%; stage III/IV: PFS 20%/OS 32%; p=<.0001 and .0002, respectively). 4-year PFS and OS for Ind were 44% and 66%, respectively, with no differences between stages. See below table for univariate prognostic factors. Multivariate cox regression for Agg NHL showed that stage III/IV, ADL loss, and < CR correlated with inferior PFS/OS. The latter 2 were significant for Ind NHL. Conclusions: Geriatric assessment tools are powerful predictors of outcome complementing standard prognostic features. Incorporation of geriatric prognostic models should be prospectively studied. Factors PFS (p/HR) OS (p/HR) Agg NHL (n=162). PS 2-4 .01/1.69 .0003/2.35 ↑LDH .03/1.5 .02/1.68 ↓ Albumin NS .0003/1.35 ↓ ADLs <.0001/2.89 <.0001/3.87 ↑ Creatinine NS .02/1.67 ↓ Platelets NS .02/1.73 Stage III/IV .0001/2.4 .0003/2.49 BM + .005/1.93 NS No CR to 1st Tx <.0001/2.88 .0002/2.35 Any CIRS 4 NS .004/1.99 Any geriatric syndrome NS .007/1.77 IPI 3-5 .002/1.91 .005/2.26 Ind NHL (n=126). Weight loss > 10% NS .003/2.81 PS 2-4 NS .045/1.39 No CR to 1st Tx .01/2.19 .006/2.91 ↓ ADLs .002/3.58 .0002/5.56 Any geriatric syndrome .01/1.86 NS Abbreviations: NS, not significant; BM, bone marrow; HR, hazard ratio.
A Prospective Study Evaluating the Safety and Efficacy of Combination Therapy with Fludarabine Plus Mitoxantrone Followed by Yttrium-90 (90Y) Ibritumomab Tiuxetan (Zevalin®) and Maintenance Rituximab as Front Line Therapy for Patients with Intermediate or High Risk Follicular Non-Hodgkin’s Lymphoma.
Authors: Stephanie A. Gregory, Mohamad Kassar, Henry C. Fung, Parameswaran Venugopal, Teresa M. O’Brien, Michelle Tenuto
Journal: Blood (2007)
Long Term Dose-Dependent Correction of Hemophilia A Dogs Using AAV-8 and AAV-9-Mediated FVIII Gene Transfer.
Authors: Denise E. Sabatino, Amy M. Lange, Melinda Mucci, Rita Sarkar, Aaron M. Dillow, Timothy C. Nichols, Valder R. Arruda, Haig H. Kazazian
Journal: Blood (2006)
P1.05-038 Patterns of Recurrence in Curatively Resected Stage I Lung Cancer
Authors: Kanghoon Lee, Dong Kwan Kim, Seung-Il Park, Yong-Hee Kim, Hyeong Ryul Kim, Se Hoon Choi, Han Pil Lee, Byung Kwon Chong, Jin San Bok, Su Kyung Hwang
Journal: Journal of Thoracic Oncology (2017)
Overexpression of Activation-Induced Deaminase in TCL1 Mice Leads to the Development of IGHV -Mutated and -Unmutated CLL Clones That Resemble Unique Subsets of Human CLL
Authors: Xiao-Jie Yan, Pablo Morande, Ezra B Kolitz, Crystal D Grant, Gautam Nayyar, Pablo Oppezzo, Nicholas Chiorazzi
Journal: Blood (2015)
Preliminary Results of Fixed-Dose Oral Clofarabine (CLO) In Patients Who Have Failed Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes (MDS)
Authors: Mikkael A. Sekeres, Gail J. Roboz, Olatoyosi Odenike, Edward Agura, Bayard L. Powell, Reginald Ewesuedo, Michael J. Vasconcelles, Stefan Faderl, Hagop Kantarjian
Journal: Blood (2010)